European Journal of Clinical Pharmacology

, Volume 65, Issue 5, pp 503–510

Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers

  • Antonio Rusca
  • Andrea Francesco Daniele Di Stefano
  • Mira V. Doig
  • Claudia Scarsi
  • Emilio Perucca
Pharmacokinetics and Disposition

Abstract

Objectives

To assess the comparative pharmacokinetic profile and bioavailability of docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA) after multiple-dose administration of a new oral formulation (test formulation) and a commercially available reference formulation in healthy subjects.

Methods

Forty-eight healthy subjects received a 28-day oral treatment with DHA/EPA in the form of either the test or the reference product according to an open-label, randomized, parallel-group design. Both formulations were given t.i.d. at 8-h intervals at a dose of 3.0 g/day. Steady-state DHA and EPA concentrations in plasma and lysed whole blood were measured by gas-liquid chromatography at baseline and after 7, 14, 21 and 28 days of treatment. Kinetic parameters were compared both after subtraction of baseline concentrations and by using baseline concentrations as a covariate.

Results

For both DHA and EPA, plasma and RBC concentrations measured from day 7 to day 28 were significantly higher than at baseline and did not differ significantly between the two products. On day 28 the plasma DHA concentration on average doubled the baseline level after administration of test and reference product, while there was a 10-fold increase in EPA plasma concentration. When the assessment was performed using baseline values as covariate, test-to-reference ratios for area under the curve (AUCss0–8) and for peak concentration (Cssmax) after the last administration on day 28 met bioequivalence criteria (i.e., 90% confidence intervals within 0.80–1.25 for AUCss0–8 ratios, and within 0.75–1.33 for Cssmax ratios). When the assessment was conducted after subtraction of baseline values, the 90% confidence intervals for Cssmax ratios were within the bioequivalence range, whereas the intervals for AUCss0–8 ratio were borderline for bioequivalence.

Conclusion

The two formulations tested were similarly effective in increasing DHA and EPA concentrations in plasma and lysed whole blood, and showed comparable bioavailability for both active components.

Keywords

Docosahexaenoic acid Eicosapentaenoic acid ω-3 fatty acids Bioavailability Humans 

References

  1. 1.
    Piscione F, Pignalberi C, Totteri A, Messina F, Altamura G (2007) Cardiovascular effects of omega-3 free fatty acids. Curr Vasc Pharmacol 5(2):163–172CrossRefGoogle Scholar
  2. 2.
    Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, Keck PE Jr, Marangell LB, Richardson AJ, Lake J, Stoll AL (2006) Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 67(12):1954–1967PubMedCrossRefGoogle Scholar
  3. 3.
    Lee S, Gura KM, Kim S, Arsenault DA, Bistrian BR, Puder M (2006) Current clinical applications of omega-6 and omega-3 fatty acids. Nutr Clin Pract 21(4):323–341PubMedCrossRefGoogle Scholar
  4. 4.
    Weber HS, Selimi D, Huber G (2006) Prevention of cardiovascular diseases and highly concentrated n-3 polyunsaturated fatty acids (PUFAs). Herz 31(Suppl 3):24–30PubMedGoogle Scholar
  5. 5.
    Ruxton CH, Reed SC, Simpson MJ, Millington KJ (2007) The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence. J Hum Nutr Diet 20(3):275–285PubMedCrossRefGoogle Scholar
  6. 6.
    von Schacky C (2007) Omega-3 fatty acids and cardiovascular disease. Curr Opin Clin Nutr Metab Care 10(2):129–135CrossRefGoogle Scholar
  7. 7.
    He K, Rimm EB, Merchant A et al (2002) Fish consumption and risk of stroke in men. JAMA 288(24):3130–3135PubMedCrossRefGoogle Scholar
  8. 8.
    Burr ML, Fehily AM, Gilbert JF et al (1989) Effects of changes in fat, fish, and fibres intake on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 2:757–761PubMedCrossRefGoogle Scholar
  9. 9.
    Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354:47–55CrossRefGoogle Scholar
  10. 10.
    Gibney MJ, Daly E (1994) The incorporation of n-3 polyunsaturated fatty acids into plasma lipid and lipoprotein fractions in the postprandial phase in healthy volunteers. Eur J Clin Nutr 48:866–872PubMedGoogle Scholar
  11. 11.
    Hodge J, Sanders K, Sinclair AJ (1993) Differential utilization of eicosapentaenoic acid and docosahexaenoic acid in human plasma. Lipids 28(6):525–531PubMedCrossRefGoogle Scholar
  12. 12.
    Marsen TA, Pollok M, Oette K et al (1992) Pharmacokinetics of omega-3-fatty acids during ingestion of fish oil preparations. Prostaglandins Leukot Essent Fat Acids 46(3):191–196CrossRefGoogle Scholar
  13. 13.
    Marangoni F, Angeli MT, Colli S et al (1993) Changes of n-3 and n-6 fatty acids in plasma and circulating cells of normal subjects, after prolonged administration of 20:5 (EPA) and 22:6 (DHA) ethyl esters and prolonged washout. Biochim Biophys Acta 1210(1):55–62PubMedGoogle Scholar
  14. 14.
    Vidgren HM, Agren JJ, Schwab U, Rissanen T, Hänninen O, Uusitupa MI (1997) Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men. Lipids 32(7):697–705PubMedCrossRefGoogle Scholar
  15. 15.
    Cao J, Schwichtenberg KA, Hanson NQ, Tsai MY (2006) Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. Clin Chem 52(12):2265–2272PubMedCrossRefGoogle Scholar
  16. 16.
    Bruno MJ, Koeppe RE, Andersen OS (2007) Docosahexaenoic acid alters bilayer elastic properties. Proc Natl Acad Sci USA 104(23):9638–9643PubMedCrossRefGoogle Scholar
  17. 17.
    Lundbaek JA, Andersen OS (1994) Lysophospholipids modulate channel function by altering the mechanical properties of lipid bilayers. J Gen Physiol 104(4):645–673PubMedCrossRefGoogle Scholar
  18. 18.
    Lund EK, Harvey LJ, Ladha S, Clark DC, Johnson IT (1999) Effects of dietary fish oil supplementation on the phospholipid composition and fluidity of cell membranes from human volunteers. Ann Nutr Metab 43(5):290–300PubMedCrossRefGoogle Scholar
  19. 19.
    Arterburn LM, Hall EB, Oken H (2006) Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 83(6 Suppl):1467S–1476SPubMedGoogle Scholar
  20. 20.
    Department of Health and Human Services and U.S. Department of Agriculture (2005) Dietary guidelines for Americans. http://www.health.gov/DietaryGuidelines/dga2005/document/default.htm. Accessed 18 Dec 2008
  21. 21.
    Schuirmann DJ (1990) Design of bioavailability/bioequivalence studies. Drug Inf J 24:315–323Google Scholar
  22. 22.
    The European Agency for the Evaluation of Medicinal Products (EMEA) (2001) Note for guidance on the investigation of bioavailability and bioequivalence. Guideline CPMP/EWP/QWP/1401/98. http://www.emea.europa.eu/pdfs/human/qwp/140198en.pdf. Accessed 18 Dec 2008
  23. 23.
    U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2003) Guidance for industry—bioavailability and bioequivalence studies for orally administered drug products. General considerations. http://www.fda.gov/Cder/guidance/5356fnl.htm. Accessed 18 Dec 2008
  24. 24.
    Food and Drug Administration, Advisory Committee for Pharmaceutical Science (2004) Briefing information: bioequivalence requirements for highly variable drugs and drug products. Washington DCGoogle Scholar
  25. 25.
    Tothfalusi L, Endrenyi L, Midha KK et al (2001) Evaluation of the bioequivalence of highly variable drugs and drug products. Pharm Res 18:728–733PubMedCrossRefGoogle Scholar
  26. 26.
    Tothfalusi L, Endrenyi L (2003) Limits for the scaled average bioequivalence of highly variable drugs and drug products. Pharm Res 20:382–389PubMedCrossRefGoogle Scholar
  27. 27.
    Tothfalusi L, Endrenyi L, Midha KK (2003) Scaling or wider bioequivalence limits for highly variable drugs and for the special case of Cmax. Int J Clin Pharmacol Ther 41:217–225PubMedGoogle Scholar
  28. 28.
    Marzo A (1999) Open questions on bioequivalence: some problems and some solutions. Pharmacol Res 40(4):357–368PubMedCrossRefGoogle Scholar
  29. 29.
    SAS/STAT user’s guide, version 8.2Google Scholar
  30. 30.
    Thermo Electron (2005) Kinetica 4.4.1 user’s manual. Waltham, MAGoogle Scholar
  31. 31.
    Blonk MC, Bilo HJ, Nauta JJ, Popp-Snijders C, Mulder C, Donker AJ (1990) Dose-response effects of fish-oil supplementation in healthy volunteers. Am J Clin Nutr 52(1):120–127PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Antonio Rusca
    • 3
  • Andrea Francesco Daniele Di Stefano
    • 3
  • Mira V. Doig
    • 2
  • Claudia Scarsi
    • 1
  • Emilio Perucca
    • 4
  1. 1.IBSA, Institut Biochimique SAPambio-NorancoSwitzerland
  2. 2.ABS Laboratories Ltd.LondonUK
  3. 3.Cross Research S.A.ArzoSwitzerland
  4. 4.Institute of Neurology, IRCCS C. Mondino Foundation and Clinical Pharmacology UnitUniversity of PaviaPaviaItaly

Personalised recommendations